Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

CuII(atsm) Attenuates Neuroinflammation.

Choo XY, Liddell JR, Huuskonen MT, Grubman A, Moujalled D, Roberts J, Kysenius K, Patten L, Quek H, Oikari LE, Duncan C, James SA, McInnes LE, Hayne DJ, Donnelly PS, Pollari E, Vähätalo S, Lejavová K, Kettunen MI, Malm T, Koistinaho J, White AR, Kanninen KM.

Front Neurosci. 2018 Sep 24;12:668. doi: 10.3389/fnins.2018.00668. eCollection 2018.

2.

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, Whittington DA, Huang X, Poppe L, Cheng AC, Cardozo M, Houze J, Li Y, Lucas B, Paras NA, Wang X, Taygerly JP, Vimolratana M, Zancanella M, Zhu L, Cajulis E, Osgood T, Sun J, Damon L, Egan RK, Greninger P, McClanaghan JD, Gong J, Moujalled D, Pomilio G, Beltran P, Benes CH, Roberts AW, Huang DC, Wei A, Canon J, Coxon A, Hughes PE.

Cancer Discov. 2018 Dec;8(12):1582-1597. doi: 10.1158/2159-8290.CD-18-0387. Epub 2018 Sep 25. Erratum in: Cancer Discov. 2019 Jul;9(7):980.

PMID:
30254093
3.

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.

Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, Macraild S, Zhang L, Teh TC, Tiong IS, Lan P, Chanrion M, Claperon A, Rocchetti F, Zichi A, Kraus-Berthier L, Wang Y, Halilovic E, Morris E, Colland F, Segal D, Huang D, Roberts AW, Maragno AL, Lessene G, Geneste O, Wei AH.

Leukemia. 2019 Apr;33(4):905-917. doi: 10.1038/s41375-018-0261-3. Epub 2018 Sep 10.

4.

Effect of Structural Modifications to Glyoxal-bis(thiosemicarbazonato)copper(II) Complexes on Cellular Copper Uptake, Copper-Mediated ATP7A Trafficking, and P-Glycoprotein Mediated Efflux.

Acevedo KM, Hayne DJ, McInnes LE, Noor A, Duncan C, Moujalled D, Volitakis I, Rigopoulos A, Barnham KJ, Villemagne VL, White AR, Donnelly PS.

J Med Chem. 2018 Feb 8;61(3):711-723. doi: 10.1021/acs.jmedchem.7b01158. Epub 2018 Jan 8.

PMID:
29232129
5.

Altered B-lymphopoiesis in mice with deregulated thrombopoietin signaling.

Au AE, Lebois M, Sim SA, Cannon P, Corbin J, Gangatirkar P, Hyland CD, Moujalled D, Rutgersson A, Yassinson F, Kile BT, Mason KD, Ng AP, Alexander WS, Josefsson EC.

Sci Rep. 2017 Nov 2;7(1):14953. doi: 10.1038/s41598-017-15023-2.

6.

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P, Thompson E, Ekert PG, Lessene G, Glaser SP, Huang DCS, Roberts AW, Guthridge MA, Wei AH.

Leukemia. 2018 Feb;32(2):303-312. doi: 10.1038/leu.2017.243. Epub 2017 Jul 28.

PMID:
28751770
7.

TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway.

Moujalled D, Grubman A, Acevedo K, Yang S, Ke YD, Moujalled DM, Duncan C, Caragounis A, Perera ND, Turner BJ, Prudencio M, Petrucelli L, Blair I, Ittner LM, Crouch PJ, Liddell JR, White AR.

Hum Mol Genet. 2017 May 1;26(9):1732-1746. doi: 10.1093/hmg/ddx093.

PMID:
28334913
8.

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Gravé F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O.

Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19.

PMID:
27760111
9.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NN, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Sep 12;30(3):499-500. doi: 10.1016/j.ccell.2016.08.009. Epub 2016 Sep 12. No abstract available.

10.

Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.

Moujalled D, White AR.

CNS Drugs. 2016 Mar;30(3):227-43. doi: 10.1007/s40263-016-0317-8. Review.

PMID:
26895253
11.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NY, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Feb 8;29(2):145-58. doi: 10.1016/j.ccell.2016.01.006. Erratum in: Cancer Cell. 2016 Sep 12;30(3):499-500.

12.

In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-κB and activation of caspase-8.

Gentle IE, Wong WW, Evans JM, Bankovacki A, Cook WD, Khan NR, Nachbur U, Rickard J, Anderton H, Moulin M, Lluis JM, Moujalled DM, Silke J, Vaux DL.

J Biol Chem. 2016 Jan 29;291(5):2547. doi: 10.1074/jbc.A110.216226. No abstract available.

13.

Phosphorylation of hnRNP K by cyclin-dependent kinase 2 controls cytosolic accumulation of TDP-43.

Moujalled D, James JL, Yang S, Zhang K, Duncan C, Moujalled DM, Parker SJ, Caragounis A, Lidgerwood G, Turner BJ, Atkin JD, Grubman A, Liddell JR, Proepper C, Boeckers TM, Kanninen KM, Blair I, Crouch PJ, White AR.

Hum Mol Genet. 2015 Mar 15;24(6):1655-69. doi: 10.1093/hmg/ddu578. Epub 2014 Nov 19.

PMID:
25410660
14.

Mitochondrial apoptosis is dispensable for NLRP3 inflammasome activation but non-apoptotic caspase-8 is required for inflammasome priming.

Allam R, Lawlor KE, Yu EC, Mildenhall AL, Moujalled DM, Lewis RS, Ke F, Mason KD, White MJ, Stacey KJ, Strasser A, O'Reilly LA, Alexander W, Kile BT, Vaux DL, Vince JE.

EMBO Rep. 2014 Sep;15(9):982-90. doi: 10.15252/embr.201438463. Epub 2014 Jul 2.

15.

RIPK1- and RIPK3-induced cell death mode is determined by target availability.

Cook WD, Moujalled DM, Ralph TJ, Lock P, Young SN, Murphy JM, Vaux DL.

Cell Death Differ. 2014 Oct;21(10):1600-12. doi: 10.1038/cdd.2014.70. Epub 2014 Jun 6.

16.

Platelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways.

Josefsson EC, Burnett DL, Lebois M, Debrincat MA, White MJ, Henley KJ, Lane RM, Moujalled D, Preston SP, O'Reilly LA, Pellegrini M, Metcalf D, Strasser A, Kile BT.

Nat Commun. 2014 Mar 17;5:3455. doi: 10.1038/ncomms4455.

PMID:
24632563
17.

Deregulation of subcellular biometal homeostasis through loss of the metal transporter, Zip7, in a childhood neurodegenerative disorder.

Grubman A, Lidgerwood GE, Duncan C, Bica L, Tan JL, Parker SJ, Caragounis A, Meyerowitz J, Volitakis I, Moujalled D, Liddell JR, Hickey JL, Horne M, Longmuir S, Koistinaho J, Donnelly PS, Crouch PJ, Tammen I, White AR, Kanninen KM.

Acta Neuropathol Commun. 2014 Feb 28;2:25. doi: 10.1186/2051-5960-2-25.

18.

Necroptosis induced by RIPK3 requires MLKL but not Drp1.

Moujalled DM, Cook WD, Murphy JM, Vaux DL.

Cell Death Dis. 2014 Feb 27;5:e1086. doi: 10.1038/cddis.2014.18.

19.

Kinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress.

Moujalled D, James JL, Parker SJ, Lidgerwood GE, Duncan C, Meyerowitz J, Nonaka T, Hasegawa M, Kanninen KM, Grubman A, Liddell JR, Crouch PJ, White AR.

PLoS One. 2013 Jun 26;8(6):e67433. doi: 10.1371/journal.pone.0067433. Print 2013.

20.

CREB-binding protein (CBP) regulates β-adrenoceptor (β-AR)-mediated apoptosis.

Lee YY, Moujalled D, Doerflinger M, Gangoda L, Weston R, Rahimi A, de Alboran I, Herold M, Bouillet P, Xu Q, Gao X, Du XJ, Puthalakath H.

Cell Death Differ. 2013 Jul;20(7):941-52. doi: 10.1038/cdd.2013.29. Epub 2013 Apr 12.

21.

TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1.

Moujalled DM, Cook WD, Okamoto T, Murphy J, Lawlor KE, Vince JE, Vaux DL.

Cell Death Dis. 2013 Jan 17;4:e465. doi: 10.1038/cddis.2012.201.

22.
23.

In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-kappaB and activation of caspase-8.

Gentle IE, Wong WW, Evans JM, Bankovacki A, Cook WD, Khan NR, Nachbur U, Rickard J, Anderton H, Moulin M, Lluis JM, Moujalled DM, Silke J, Vaux DL.

J Biol Chem. 2011 Apr 15;286(15):13282-91. doi: 10.1074/jbc.M110.216226. Epub 2011 Feb 21. Erratum in: J Biol Chem. 2016 Jan 29;291(5):2547.

24.

The PKA paradox: is Bim the answer?

Coley AM, Moujalled D, Puthalakath H.

Cell Cycle. 2011 Mar 1;10(5):729-30. Epub 2011 Mar 1. No abstract available.

PMID:
21311230
25.

Cyclic-AMP-dependent protein kinase A regulates apoptosis by stabilizing the BH3-only protein Bim.

Moujalled D, Weston R, Anderton H, Ninnis R, Goel P, Coley A, Huang DC, Wu L, Strasser A, Puthalakath H.

EMBO Rep. 2011 Jan;12(1):77-83. doi: 10.1038/embor.2010.190. Epub 2010 Dec 10.

26.

TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.

Lluis JM, Nachbur U, Cook WD, Gentle IE, Moujalled D, Moulin M, Wong WW, Khan N, Chau D, Callus BA, Vince JE, Silke J, Vaux DL.

PLoS One. 2010 Jan 8;5(1):e8620. doi: 10.1371/journal.pone.0008620. Erratum in: PLoS One. 2010;5(12) doi: 10.1371/annotation/4e35cd59-c68f-4020-addb-18eb896112c5.

Supplemental Content

Loading ...
Support Center